EUVIMEDEUVIMED entdecken
Kohortenstudie

Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study

Yaping Hong, Rongqi Jiang, Shijie Chen, Dongzhu Lu, Jinlan Lin, Pan Huang, Jingyi Qu, Junfei Deng, Jingqi He, Yunjian Huang, Jinhuo Lai

Journal of Neuro-Oncology · 2026-07 · 178 (3)

DOI: 10.1007/s11060-026-05677-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 26.06.2026. Verfasst von Yaping Hong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nomograms, Lung Neoplasms, Meningeal Carcinomatosis. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Leptomeningeal metastasis (LM) carries a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to explore clinical features and survival outcomes and develop a nomogram for overall survival (OS) in this population.

Methods

We retrospectively enrolled 288 EGFR-mutant NSCLC patients with LM from Fujian Cancer Hospital (January 2019–March 2024). Prognostic variables were selected by LASSO regression followed by multivariable Cox proportional hazards modeling. Internal validation used 1000-iteration bootstrap resampling. Model performance was assessed by the time-dependent area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis.

Results

Median OS was 16.2 months. Before LM, 71.5% of patients received third-generation EGFR tyrosine kinase inhibitors (TKIs), and 76.7% received third-generation EGFR-TKI therapy after LM. Eight variables were identified by LASSO-Cox regression: ECOG performance status (PS), prior lines of systemic therapy, cranial MRI findings, third-generation EGFR-TKI therapy before and after LM, antiangiogenic therapy after LM, chemotherapy after LM, and CNS radiotherapy after LM. Post-LM third-generation EGFR-TKI therapy was the strongest treatment-associated prognostic factor (HR = 2.23; p < 0.001), with survival benefit maintained regardless of prior third-generation EGFR-TKI exposure (prior-exposed: HR = 0.60, p = 0.029; TKI-naïve: HR = 0.18, p < 0.001). The nomogram demonstrated good discrimination (AUC: 0.777, 0.778, and 0.742 for 6-, 12-, and 18-month OS; C-index: 0.716).

Conclusion

In EGFR-mutant NSCLC patients with LM, post-LM third-generation EGFR-TKI therapy was associated with longer survival, regardless of prior third-generation EGFR-TKI use. The nomogram may support individualized risk stratification but requires external validation in independent multi-institutional cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNomogramsLung NeoplasmsMeningeal CarcinomatosisHumansFemaleMaleErbB ReceptorsRetrospective StudiesPrognosisMutationMiddle AgedAgedProtein Kinase InhibitorsSurvival RateFollow-Up StudiesAdult

Stichwörter der Autor:innen

Epidermal growth factor receptorLeptomeningeal metastasisNon-small cell lung cancerOverall survivalPrognostic nomogramTyrosine kinase inhibitor

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
  • Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, 350014, China.
  • Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
  • The Second Clinical School of Fujian Medical University, Quanzhou, Fujian, China.
  • Fujian Medical University Union Hospital, Fuzhou, Fujian, China.

Zitieren

APA

Hong, Y., Jiang, R., Chen, S., Lu, D., Lin, J., Huang, P., Qu, J., Deng, J., He, J., Huang, Y., & Lai, J. (2026). Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study. Journal of Neuro-Oncology, 178(3). https://doi.org/10.1007/s11060-026-05677-2

Vancouver

Hong Y, Jiang R, Chen S, Lu D, Lin J, Huang P, et al. Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study. Journal of Neuro-Oncology. 2026;178(3). doi:10.1007/s11060-026-05677-2

BibTeX
@article{Hong2026,
  author = {Hong, Yaping and Jiang, Rongqi and Chen, Shijie and Lu, Dongzhu and Lin, Jinlan and Huang, Pan and Qu, Jingyi and Deng, Junfei and He, Jingqi and Huang, Yunjian and Lai, Jinhuo},
  title = {Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {178},
  number = {3},
  doi = {10.1007/s11060-026-05677-2}
}
Kostenlos starten →